Becton Dickinson and CompanyBDX
▲ PositiveCapitalrelevance
Raises full-year EPS guidance after strong Q3 beat
Impact on stocks 1
Biotech & Genomic Medicine
Becton Dickinson and CompanyBD reported fiscal third quarter 2026 revenue of $5 billion, up 4.4%, with adjusted EPS of $3.23, beating expectations and prompting the company to raise the midpoint of its full-year adjusted EPS guidance to a range of $12.62 to $12.72. CEO Tom Polen said more than 90% of the portfolio delivered high single-digit growth, driven by double-digit gains in biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration, while known headwinds in Alaris and China vaccines played out as expected. CFO Vitor Roque noted adjusted operating margin was 24.9%, down 130 basis points year over year due to about 110 basis points of tariff impact, and free cash flow rose 45% year-to-date to $1.7 billion. The company reiterated that fiscal 2027 revenue growth is expected to be low single digits, with a 200 basis point headwind from the end of Alaris remediation, and said it will provide formal guidance in November.
Becton Dickinson and CompanyRaises full-year EPS guidance after strong Q3 beat